IDEX CORP /DE/ (IEX) Company Report

IDEX delivered 5% organic sales growth, 7% order growth, and 40 bps adjusted EBITDA margin expansion in Q3 2025, led by strong HST performance.
The Health & Science Technology segment posted 10% sales growth, 5% orders growth, and 120 bps margin expansion on volume leverage, platform savings, and pricing actions.
Fluid & Metering Technologies remained flattish, while Fire & Safety/Diversified Products faced headwinds from funding disruptions and subdued replenishment spend.
Free cash flow reached $189 million (123% of adjusted net income), and IDEX repurchased $75 million of shares in the quarter, totaling $175 million year-to-date.
Management continues to apply its 80/20 discipline and integrate recent acquisitions (e.g., Microlam, Nexsight, Subterra) to target advantaged markets such as water, data centers, and material science.

Oct 29, 2025, 1:00 PM

Transcript

IDEX announces Q3 2025 results

IEX

Earnings

Guidance Update

Share Buyback

IDEX delivered 7% organic orders growth and 5% organic revenue growth in Q3 2025, led by strong HST momentum with a record $390 million in orders.
Health & Science Technology (HST) posted 5% organic orders growth, 10% sales growth, and 120 bps EBITDA margin expansion; Fluid & Metering Technologies (FMT) saw 8% orders growth, 4% sales growth, and 90 bps margin improvement.
Fire & Safety/Diversified Products (FSDP) segment orders rose 7%, but sales declined 5%, resulting in a 200 bps EBITDA margin contraction.
Free cash flow was $189 million with 123% conversion, liquidity of $1.1 billion, and $75 million of share repurchases in Q3 (**$175 million** YTD); buyback authorization increased to $1 billion.
Full year guidance narrowed to $7.86–$7.91 EPS, with unchanged 1% organic growth and 26.5–27.5% adjusted EBITDA margin outlook.

Oct 29, 2025, 1:00 PM

Transcript

IDEX reports Q3 2025 results

IEX

Earnings

Share Buyback

IDEX delivered 5% organic revenue growth and 7% organic order growth in Q3, with adjusted EBITDA margin expanding 40 bps year-over-year.
The Health and Science Technology (HST) segment achieved organic orders +5%, sales +10%, and adjusted EBITDA margin +120 bps.
IDEX generated $189 M of free cash flow (123% conversion) and repurchased $75 M of shares in Q3 (YTD $175 M), maintaining $1.1 B of liquidity.
Platform optimization and cost containment initiatives delivered $17 M in Q3 savings, on track for over $60 M of full-year savings.

Oct 29, 2025, 1:00 PM

Transcript

IDEX reports Q3 2025 results

IEX

Earnings

Guidance Update

Share Buyback

Record Q3 orders of $880 million (+13% reported, +7% organic) and sales of $879 million (+10% reported, +5% organic).
GAAP diluted EPS of $1.70 (+8%) and adjusted diluted EPS of $2.03 (+7%).
Narrowed full-year 2025 EPS guidance to $6.35–6.40 (GAAP) and $7.86–7.91 (adjusted).
Returned capital with $75 million of share repurchases in Q3 (YTD $175 million) and raised buyback authorization to $1 billion.

Oct 29, 2025, 11:08 AM

8-K

IDEX reports record Q3 sales and EPS growth

IEX

Earnings

Guidance Update

Share Buyback

Record Q3 net sales of $879 million, up 10% year-over-year (5% organically), and adjusted diluted EPS of $2.03, up 7%.
Record Q3 orders of $880 million, up 13% year-over-year (7% organically).
Narrowed full-year 2025 GAAP EPS outlook to $6.35–$6.40 (adjusted EPS $7.86–$7.91) while maintaining ~1% organic sales growth guidance.
Share repurchases of $75 million in Q3 and $175 million YTD; authorization increased to $1 billion.

Oct 29, 2025, 11:00 AM

Press Release

IDEX Biometrics launches new product portfolio for payment and access solutions

IEX

Product Launch

IDEX Biometrics rolled out a new product portfolio for payment and access solutions alongside a redesigned website to showcase its advanced biometric authentication offerings.
The launch completes IDEX’s transformation from a component supplier to a fully-fledged product company, strengthening its value proposition and potential for recurring revenue.
In Q3, IDEX entered into multiple partnerships via Letters of Intent and began product testing, targeting commercial launches throughout 2025.
The company is focusing on the Zero Trust security market (projected to grow from $42.91 billion in 2025 to $92.42 billion by 2030) and the digital payment fraud detection market (forecast to expand from $8.1 billion to $20.0 billion by 2032).

Sep 11, 2025, 5:02 AM

Press Release

IDEX Corp reports Q2 2025 results and lowers guidance

IEX

Earnings

Guidance Update

Share Buyback

Q2 organic orders grew 2% and organic sales 1%, with adjusted EBITDA margin of 27.4% and free cash flow of $147 million (94% conversion).
Full-year organic revenue growth guidance cut to ~1% (from 1–3%), adjusted EPS lowered to $7.85–$7.95 (from $8.10–$8.45); Q3 organic revenue is now expected at 2–3% with EPS of $1.90–$1.95.
Trade policy–driven order volatility created “up and down” day rates, slowing larger-order decision-making and moderating back-half expectations, particularly in the MSS platform and Mott segment.
Strong liquidity of $1.1 billion, including $568 million cash; repurchased $50 million of shares in Q2 ($100 million YTD) with $440 million remaining authorization; prioritizing tuck-in M&A and buybacks.

Jul 30, 2025, 10:45 PM

IDEX CFO Resignation and Interim Appointment Announcement

IEX

CFO Change

Management Change

Executive Compensation

Abhishek Khandelwal resigns as CFO effective May 30, 2025 to pursue a new opportunity, with no disputes over accounting or disclosure matters.
Akhil Mahendra is appointed interim CFO and awarded a restricted stock grant worth $500,000, vesting in three years.

May 21, 2025, 12:00 AM

8-K

IDEX Corp Q1 2025 Results, Guidance & Financial Highlights

IEX

Earnings

Guidance Update

M&A

Share Buyback

IDEX delivered Q1 2025 results with record orders of $872M, net sales of $814M (2% YoY increase, 1% organic decline), and record backlog growth alongside improved adjusted EBITDA margins driven by targeted wins and price-cost optimization .
The company reported diluted EPS of $1.26 (down 21%) and adjusted EPS of $1.75 (down 7%) in Q1 2025 .
Proactive cost savings initiatives, including an additional $20M reduction to offset volume headwinds, bolstered revenue and margins .
Full year guidance was maintained with 1-3% organic growth and $8.10-$8.45 adjusted EPS, while Q2 revenue is expected to grow flat to 2% aided by tariff mitigation and strategic pricing adjustments .
Strategic initiatives focused on integrating business segments through delayering and M&A, complemented by a robust capital deployment program featuring a $50M share repurchase supported by strong free cash flow .

May 1, 2025, 1:01 PM

Transcript Presentation 8-K

Earnings Transcripts

Quarterly earnings call transcripts for IDEX CORP /DE/.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Eric Ashleman say about margins?What are IDEX CORP /DE/'s strategic priorities?How is IDEX CORP /DE/ positioned vs competitors?How did IDEX CORP /DE/ do last quarter?

Let Fintool AI Agent track IDEX CORP /DE/'s earnings for you

Get instant analysis when filings drop